Evidence map›Paper›PMID 40418165›Full record

SynthesisFuture cardiology2025

Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis.

Aymen Ahmed, Muhammad Umer Sohail, Muhammad Saad, Zara Naveed, Muhammad Sameer Arshad, Areesha Jawed, Adeena Musheer, Anousheh Awais Paracha, Ahmed Kamal Siddiqi, Neha Saleem Paryani and 2 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aymen AhmedDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Muhammad Umer SohailDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Muhammad SaadDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Zara NaveedDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Muhammad Sameer ArshadDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Areesha JawedDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Adeena MusheerDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Anousheh Awais ParachaDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Ahmed Kamal SiddiqiDivision of Cardiothoracic Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.
Neha Saleem ParyaniDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Izza ShahidDivision of Preventive Cardiology, Houston Methodist Academic Institute, Houston, TX, USA.
Muhammad Mustafa MemonDepartment of Medicine, Rochester General Hospital, Rochester, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundST-segment elevation myocardial infarction (STEMI) is responsible for high morbidity and mortality rates globally. Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs. This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI.

methodsRandomized controlled trials (RCTs) were pooled from PubMed and Cochrane databases. A random-effects model calculated risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs).

resultsFive trials (

conclusionsARNI therapy reduces MACE, HHF, and NT-proBNP levels and improves LVEF in patients with STEMI without increasing safety risks, except for hypotension. Further RCTs are needed to confirm these findings.

Indexed as

Angiotensin Receptor AntagonistsNeprilysinST Elevation Myocardial InfarctionAngiotensin-Converting Enzyme InhibitorsHumansRandomized Controlled Trials as TopicStroke VolumeTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsNeprilysinAngiotensin receptor neprilysin inhibitorscardiovascular outcomesheart failuremeta-analysisSTEMI

Identifiers

PMID40418165
PMCPMC12150624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.